Mouse xenograft experiments using Ph+ ALL cells derived from patients after relapse during ongoing therapy with the Abl inhibitor Imatinib (Gleevec) showed these to be resistant to tyrosine kinase inhibition, but sensitive to treatment with BCI, indicating that this drug might be used to treat TKI-resistant Ph+ ALL [164]. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.